Jubilant Pharmova Q2 Review: Nirmal Bang Raises Target Price, Bets On H2 Margin Recovery

Jubilant Pharmova's revenue growth remains healthy during the quarter, but earnings are being held back by the SPECT supply gap and Montreal remediation costs, says Nirmal Bang.
Affected stocks
Neutral1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Jubilant Pharmova (JUBLPHARMA).
- Category: Results.
Why it matters
A routine update for Jubilant Pharmova. Use the price and stock snapshot to gauge how the market is responding.












